Home | Harrow, Inc.
Oct 6, 2025 · Harrow is redefining the standard of care in eyecare with a portfolio of trusted, high-value pharmaceutical solutions that deliver proven safety, efficacy, and affordability.
About | Harrow, Inc.
Harrow, a leading provider of ophthalmic disease management solutions in North America, was founded with a commitment to deliver safe, effective, accessible, and affordable medications …
Harrow Launches VEVYE® Access for All
Mar 17, 2025 · Harrow, Inc. (Nasdaq: HROW) is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic …
Careers | Harrow, Inc.
At Harrow, our values aren’t just guiding words—they shape how we grow, innovate, and work together. Humility, ownership, preparedness, and entrepreneurship create the foundation for a …
Leadership | Harrow, Inc.
Prior to joining Harrow, he was Founder and Chief Executive Officer of LVMA Consulting, advising emerging biotech companies and top 10 global pharmaceutical organizations on commercial …
0001493152-25-012840 | 8-K | iXBRL Viewer | Harrow INC
Harrow INC SEC filing: Form 8-K iXBRL on 09/09/2025 (0001493152-25-012840).
www.harrow.com
www.harrow.com
Events | Harrow, Inc.
Aug 12, 2025 · Harrow, Inc. Investor & Analyst Day Presentation 6.8 MB August 13, 2025 | 1:00 PM EDT H.C. Wainwright’s 5th Annual Ophthalmology Conference - Panel discussion on …
Terms of Use | Harrow, Inc.
The content provided by Harrow on this web site and all site-related services is intended to educate and inform you about Harrow, our product candidates and our technology.
0001493152-23-040563 | 10-Q | iXBRL Viewer | Harrow INC
Harrow INC SEC filing: Form 10-Q on 11/13/2023 (0001493152-23-040563).